Fortress Biotech, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Sponsored Research and Clinical Trial Agreements (Tables)

Sponsored Research and Clinical Trial Agreements (Tables)

9 Months Ended

Sep. 30, 2018

Schedule of Expense Related to Clinical Research Arrangements

The table below provides a summary of Helocyte’s expense related to its clinical research arrangements, for the three and nine months ended September 30, 2018 and 2017, by agreement as recorded in the Condensed Consolidated Statements of Operations:

	For the Three Months Ended September 30,				For the Nine Months Ended September 30,
($ in thousands)	2018		2017		2018		2017
COH Triplex clinical research and support	$	–	$	1,300	$	–	$	2,335
COH PepVax clinical research and support		–		327		–		561
COH Pentamer clinical research and support		113		12		317		24
Total licenses acquired expense	$	113	$	1,639	$	317	$	2,920

Schedule of Expense Related to Sponsered Research Arrangements

The table below provides a summary of Mustang’s expense related to its sponsored research

and clinical trial

agreements, for the three and nine months ended September 30, 2018 and 2017, by license as recorded in the Condensed Consolidated Statements of Operations:

	For the Three Months Ended September 30,				For the Nine Months Ended September 30,
($ in thousands)	2018		2017		2018		2017
COH CAR T	$	500	$	500	$	1,500	$	1,500
COH - CD123		123		642		387		1,237
COH - IL13Rα2		346		194		849		1,204
City of Hope - Manufacturing		114		-		344		-
Fred Hutch – CD20		255		88		938		88
BIDMC – CRISPR		69		–		69		–
Total	$	1,407	$	1,424	$	4,087	$	4,029